Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
SynAct Pharma AB ( (SE:SYNACT) ) has shared an announcement.
SynAct Pharma AB announced it received SEK 17.7 million following the conversion of 1,000,000 warrants by Heights Capital Management, Inc. This financial boost strengthens SynAct’s financial position, extending its operational runway into 2027 and supporting its development opportunities and discussions with potential partners.
More about SynAct Pharma AB
SynAct Pharma AB is a clinical-stage biotechnology company listed on Nasdaq Stockholm. It focuses on resolving inflammation through the selective activation of the melanocortin system. The company offers a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation resolution activity to help patients achieve immune balance and overcome their inflammation.
Average Trading Volume: 222,948
Current Market Cap: SEK1.09B
For a thorough assessment of SYNACT stock, go to TipRanks’ Stock Analysis page.